Low Testosterone

Low testosterone affects an estimated 2–6 million American men with confirmed hypogonadism, and a much larger number of men with non-specific symptoms (low energy, reduced libido, depressed mood, decreased muscle mass) that may or may not reflect a true androgen deficiency. The clinical category divides into primary hypogonadism (testicular failure — high LH/FSH, low testosterone) and secondary hypogonadism (failure at the hypothalamic or pituitary level — low or inappropriately normal LH/FSH with low testosterone). Conventional management is testosterone replacement therapy (TRT) using injectable, transdermal, or pellet formulations, which directly raises testosterone but suppresses endogenous gonadotropins and impairs spermatogenesis — a major issue for men who want to preserve fertility.

Peptide therapy approaches low testosterone differently. Rather than supplying exogenous testosterone, peptide protocols stimulate the hypothalamic-pituitary-gonadal (HPG) axis at upstream control points. Kisspeptin and gonadorelin (GnRH) act at the hypothalamic level. hCG and hMG (and ipamorelin secondarily) act at the testicular level via LH-receptor agonism. Enclomiphene — a selective estrogen receptor modulator rather than a peptide — is often discussed alongside these because it raises endogenous testosterone by blocking estrogenic negative feedback at the hypothalamus. The unifying logic: stimulate the body's own testosterone production rather than replacing it.

This page covers when peptide-based HPG-axis stimulation is clinically appropriate versus when direct testosterone replacement is the better choice, what the evidence actually shows for each agent, and important caveats around fertility preservation, monitoring, and the difference between peptides used alongside TRT and those used as standalone alternatives. It is informational, not medical advice.

How peptides target low testosterone

The HPG axis is regulated by hierarchical hormonal signaling. Hypothalamic neurons release pulses of gonadotropin-releasing hormone (GnRH), which stimulate pituitary release of LH and FSH. LH activates testicular Leydig cells to produce testosterone; FSH supports Sertoli-cell-driven spermatogenesis. Testosterone (and its metabolite estradiol) provides negative feedback at both hypothalamus and pituitary, completing the loop. Disrupting any node alters the entire axis.

Kisspeptin sits upstream of GnRH neurons — kisspeptin neurons in the arcuate nucleus and AVPV are the master regulators of GnRH release. Exogenous kisspeptin administration powerfully stimulates GnRH, then LH/FSH, then testosterone in men with secondary hypogonadism. Kisspeptin has been studied in clinical trials primarily in fertility contexts and in characterizing the axis itself, with promising results in restoring testosterone in selected patients.

Gonadorelin is the synthetic analog of native GnRH. Pulsatile gonadorelin administration mimics the natural GnRH pulsation and can restore testosterone and spermatogenesis in men with hypothalamic-level hypogonadism. It is FDA-approved (as Lutrepulse, though no longer marketed in the US) for diagnostic use and historically for treatment of hypothalamic hypogonadism. Continuous (non-pulsatile) GnRH administration paradoxically suppresses the axis (the basis for GnRH-agonist use in prostate cancer), so the dosing regimen matters critically.

hCG is the most-used peptide for HPG-axis support in clinical practice. It binds the LH/hCG receptor on Leydig cells, directly stimulating testicular testosterone production. The classical use is in men on TRT to preserve testicular volume and intratesticular testosterone, supporting spermatogenesis (Coviello et al. 2005; Hsieh et al. 2013 demonstrating no patient on TRT plus 500 IU hCG every other day became azoospermic). It is also used in men recovering from anabolic-androgenic steroid-induced hypogonadism. hMG (containing both FSH and LH activity) is added to hCG when spermatogenesis fails to recover on hCG monotherapy alone, particularly in hypogonadotropic hypogonadism.

Enclomiphene (the trans-isomer of clomiphene) blocks estrogen receptors at the hypothalamus, removing estrogenic negative feedback on GnRH. The result is increased endogenous LH, FSH, and testosterone — without the testicular shutdown of TRT. Enclomiphene is technically a small molecule rather than a peptide, but it sits in this conversation as the most clinically established standalone alternative to TRT for men with secondary hypogonadism who want to preserve fertility.

What the evidence shows

The evidence varies dramatically across the agents. hCG has the longest clinical track record — decades of use in pediatric cryptorchidism, hypogonadotropic hypogonadism, and adjunctively with TRT. The Coviello et al. 2005 study demonstrated maintenance of intratesticular testosterone and spermatogenesis with concomitant TRT and low-dose hCG. The Hsieh et al. 2013 retrospective analysis of men on TRT plus 500 IU hCG every other day showed no patients became azoospermic, establishing the protocol that remains common practice. hMG has parallel evidence in male infertility induction in hypogonadotropic hypogonadism, where adding hMG to hCG can produce spermatogenesis when hCG alone is insufficient.

Enclomiphene has the strongest randomized human evidence among the standalone alternatives to TRT. Phase II/III studies demonstrated raised endogenous testosterone, preserved or improved sperm parameters, and improved hypogonadal symptoms. Although enclomiphene was not FDA-approved (Repros Therapeutics' NDA was rejected in 2015 over efficacy threshold concerns), it remains widely available through compounding pharmacies and is the most-prescribed standalone HPG-axis intervention in current clinical practice.

Kisspeptin has impressive mechanistic evidence — multiple human studies demonstrate dose-dependent LH and testosterone increases — but no FDA approval for hypogonadism. Most kisspeptin clinical work has been in fertility induction, characterization of the axis, and ovulation induction. Its potential as a hypogonadism therapy is real but not yet validated in pivotal trials.

Gonadorelin in pulsatile form has classic evidence in restoring fertility and testosterone in hypothalamic hypogonadism (Kallmann syndrome and similar) but is rarely used in current US practice because of the practical difficulty of pulsatile delivery (historically requiring a portable infusion pump). Daily or every-other-day gonadorelin use for low T support — common in current functional-medicine and TRT-clinic practice — is mechanistically reasonable but lacks robust RCT validation.

The broader literature on testosterone replacement itself is extensive — TRT raises testosterone reliably and improves sexual function, libido, mood, body composition, and bone density in hypogonadal men, with manageable safety profile in well-selected patients. The TRAVERSE cardiovascular outcomes trial (2023) demonstrated cardiovascular safety of TRT in middle-aged and older hypogonadal men with cardiovascular risk factors, addressing a major historical concern.

What to expect

Outcomes depend heavily on which intervention is chosen. With hCG monotherapy in primary hypogonadism: limited testosterone elevation (hCG works at the testicle, but a failed testicle responds poorly). With hCG monotherapy in secondary hypogonadism, particularly in younger men with intact testicular function: meaningful testosterone elevation, preserved testicular volume, and preserved spermatogenesis over weeks to months. The standard adjunctive regimen with TRT (500 IU twice weekly subcutaneous) preserves testicular function while exogenous testosterone supplies the systemic androgen effect.

With enclomiphene in secondary hypogonadism: testosterone elevation typically within 4–6 weeks of starting therapy, reaching steady state by 12 weeks. Symptom improvement (energy, libido, mood) tracks the testosterone elevation but is highly individual. Sperm parameters typically remain in the normal range or improve.

With kisspeptin or gonadorelin: more variable. Kisspeptin produces predictable LH/testosterone responses in research settings but is not yet a routine clinical intervention. Pulsatile gonadorelin requires specialized delivery; daily gonadorelin in TRT-clinic practice has highly variable real-world results.

What to NOT expect: a peptide-based 'cure' for primary testicular failure (Klinefelter syndrome, post-chemotherapy testicular damage, age-related primary hypogonadism — these usually require TRT). Magnitude of testosterone elevation comparable to high-dose injectable TRT (peptide-based HPG-axis stimulation generally produces mid-range, not supraphysiologic, testosterone). Independence from clinical monitoring: hematocrit, PSA, lipid panel, hormone panels, and symptom assessment are essential regardless of whether peptide stimulation or direct testosterone replacement is used.

Frequently asked questions

Part of these goals

Related conditions

• Erectile Dysfunction
• Chronic Fatigue